Ex vivo generation of cytokine-induced killer cells (CD3+ CD56+) from post-stem cell transplant pediatric patients against autologous-Epstein-Barr virus-transformed lymphoblastoid cell lines

Pediatric Transplantation

Volumn 11, Issue 5, 2007, Pages 511-517

  Petvises, Sawang ^a   Pakakasama, Samart ^b   Wongkajornsilp, Adisak ^c   Sirireung, Somtawin ^b   Panthangkool, Wanpen ^b   Hongeng, Suradej ^b,d  

^a THAMMASAT UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Mahidol University ^*  (Thailand)

Author keywords

Adoptive immunotherapy; Autologous cytokine induced killer cells; Epstein Barr virus transformed lymphoblastoid cell lines

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CYTOKINE;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL TRANSFORMATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EPSTEIN BARR VIRUS; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; KILLER CELL; LYMPHOBLASTOID CELL LINE; LYMPHOPROLIFERATIVE DISEASE; MALE; STEM CELL TRANSPLANTATION;

ADOLESCENT; ANTIGENS, CD3; ANTIGENS, CD56; CELL LINE; CELL TRANSFORMATION, VIRAL; CHILD; CHILD, PRESCHOOL; CULTURE MEDIA, SERUM-FREE; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOPHENOTYPING; MALE; PHENOTYPE; POSTOPERATIVE COMPLICATIONS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 34447298673     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00692.x     Document Type: Article

References (27)

1. Finn L, Reyes J, Bueno J, Yunis E. Epstein-Barr virus infections in children after transplantation of small intestine. Am J Surg Pathol 1998 : 22 : 299 309.
2. Green M, Michaels MG, Webber SA, Rowe D, Reyes J. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transplant 1999 : 3 : 271 281.
3. Karp JE, Broder S. Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas. Cancer Res 1991 : 51 : 4743 4756.
4. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999 : 68 : 1517 1525.
5. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signal induced through the co-receptor SLAM. Nature 1998 : 395 : 462 469.
6. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998 : 92 : 1549 1555.
7. Haque T, Crawford DH. The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation. Br J Haematol 1999 : 106 : 309 316.
8. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modifies virus-specific T lymphocytes. Nat Med 1996 : 2 : 551 555.
9. Lu PH, Negrin RS. A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo anti-tumor activity in mice with severe combined immunodeficiency. J Immunol 1994 : 153 : 1687 1696.
10. Schmidt-Wolf IG, Leftovera P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993 : 21 : 1673 1679.
11. Hongeng S, Petvises S, Worapongpaiboon S, Rerkamnuaychoke B, Pakakasama S, Jootar S. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 2003 : 77 : 175 179.
12. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005 : 11 : 181 187.
13. Mattis AE, Bernhardt G, Lipp M, Forster R. Analyzing cytotoxic T lymphocyte activity: A simple and reliable flow cytometry-based assay. J Immunol Methods 1997 : 204 : 135 142.
14. Neubauer MA, Benyunes MC, Thompson JA, et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1994 : 13 : 311 316.
15. Bosly A, Guillaume T, Brice P, et al. Effects of escalating doses of recombinant human interleukine-2 in correcting function T cell defects following sutologous bone marrow transplantation for lymphomas and solid tumors. Exp Hematol 1992 : 20 : 962 968.
16. Benyunes MC, Higuchi C, York A, et al. Immunotherapy with interleukine-2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: A feasibility trial. Bone Marrow Transplant 1995 : 16 : 283 288.
17. Hoyle C, Bangs CD, Pearl C, et al. Expansion of Philadelphia chromosome-negative CD3+ CD56+ cytotoxic cells from chronic myeloid leukemia patients in vitro and in vivo efficacy in sever combined immunodeficiency disease mice. Blood 1998 : 92 : 3318 3327.
18. Sweeney TJ, Mailänder V, Tucker AA, et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 1999 : 96 : 12044 12049.
19. Savoldo B, Goss J, Liu Z, et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 2001 : 72 : 1078 1086.
20. Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001 : 7 : 216 222.
21. Vichchatorn P, Wongkajornsilp A, Petvises S, Tangpradubkul S, Pakakasama S, Hongeng S. Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme. J Neurooncol 2005 : 75 : 111 118.
22. Wongkajornsilp A, Sangsuriyong S, Hongeng S, Waikakul S, Asavamongkolkul A, Huabprasert S. Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA pulsed dendritic cells. J Orthop Res 2005 : 23 : 1460 1466.
23. Rooney CM, Rickinson AB, Moss DJ, Lenoir GM, Epstein MA. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: Comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int J Cancer 1984 : 34 : 339 348.
24. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood 2001 : 97 : 2923 2931.
25. Verneris ME, Baker J, Edinger M, Negrin RS. Studies of ex vivo activated and expanded CD8+ NK-T cells in human and mice. J Clin Immunol 2002 : 22 : 131 136.
26. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's disease. J Exp Med 2004 : 200 : 1623 1633.
27. Camoli P, Pedrazzoli P, Maccario R, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005 : 35 : 8942 8949.